The Simple Truth
Why this exists and what it’s supposed to do.
AOD-9604 exists because someone tried to keep the fat-burning half of growth hormone and throw away the rest.
Growth hormone releases fat from fat cells, but it also raises blood sugar and makes tissue grow — side effects nobody wanted. AOD-9604 is a small piece clipped from the tail of the growth hormone molecule, chosen because in animals that piece appeared to burn fat without the blood-sugar problem.
What it is supposed to do: push the body to burn stored fat for fuel, without the side effects of growth hormone itself. That is why someone would reach for it — fat loss specifically, not muscle growth or recovery.
The animal data behind that idea is real but it is from 2001, and there is no published randomised human obesity trial. The claim is far ahead of the evidence.
A fragment's origin does not establish its effects
AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone. That origin explains its research history but does not make it interchangeable with full-length growth hormone. Nor does the phrase fat-loss fragment establish that it produces useful weight loss in humans. Identity, mechanism, clinical efficacy and safety are separate questions.
The FDA's 2024 Pharmacy Compounding Advisory Committee briefing evaluated AOD-9604 free base and acetate, including the limited clinical literature and sponsor disclosures. This is a regulatory evidence assessment, not a newly conducted randomized trial. It is particularly valuable because confident online claims often omit the unfavorable human development results.
What the mouse study found
A 2001 primary experiment compared AOD9604 and human growth hormone in obese mice and beta-3-adrenergic-receptor knockout mice. Following 14 days of intraperitoneal administration, the investigators observed reductions in body weight and fat in obese mice, together with changes in beta-3-receptor expression. Knockout experiments helped interrogate the proposed pathway.
This is animal mechanistic evidence. The model, route and duration matter: an intraperitoneal mouse experiment is not a trial of subcutaneous self-administration in humans. A mechanism supported in this system cannot establish a successful obesity treatment, absence of adverse effects, selective removal of a human fat depot or preservation of all other growth-hormone-related functions.
The larger human trial is the crucial counterweight
The FDA briefing describes the OPTIONS study: 536 adults with obesity were enrolled and 502 randomized in a double-blind placebo-controlled design. Participants received oral AOD-9604 or placebo alongside a supervised diet and exercise program over 24 weeks. FDA reports no significant difference in the primary weight-loss endpoint at 12 weeks.
The distinction between enrolled and randomized counts explains why summaries can cite different sample sizes. This was not a demonstration that every conceivable formulation or route is ineffective, but it was an important failure to confirm the marketed obesity proposition. It should not be erased by selecting a smaller favorable study or citing only animal lipolysis findings.
Changing the route does not repair missing evidence
A response to an unfavorable oral trial is sometimes to claim that injection must work better. That is a new hypothesis, not an established finding. The FDA assessment identified limitations in available clinical details and did not find evidence establishing obesity efficacy for the nominated routes. An untested route cannot inherit success from animal studies while being exempted from unfavorable human evidence.
Safety also needs more than a narrow mechanistic statement. Lack of a demonstrated effect on one hormone marker would not establish comprehensive safety, and a certificate of analytical purity does not establish sterility, endotoxin control or clinical suitability. A research vial should not be described as an approved obesity treatment merely because a peptide sequence has appeared in human development.
How to read the regulatory assessment accurately
The FDA briefing concluded that available evidence did not support effectiveness for obesity and discussed substantial limits in the clinical material. That conclusion should be attributed to the document and its scope. A compounding-advisory review is not the same thing as granting a marketing authorization, and a nomination, meeting or ingredient listing should not be represented as drug approval.
There is an equally important limit in the other direction: it would be wrong to say AOD-9604 has never been given to humans. Human studies existed; the issue is what they demonstrated and how well they were reported. This distinction makes the guide more useful than either a promotional benefit list or an inaccurate no-human-data slogan.
Questions readers actually ask
Does AOD-9604 cause human fat loss? The larger oral trial reviewed by FDA did not establish the primary weight-loss benefit, and the mouse findings do not resolve that failure. Is it simply growth hormone without the risks? Neither its fragment origin nor the cited studies establish that broad claim.
Can an injection dose or cycle be inferred from the papers? No personal regimen follows from this evidence review. What would improve confidence? Adequately reported controlled human studies of a precisely identified formulation and route, clinically meaningful outcomes and suitable safety follow-up. Until then, the substantive conclusion is a mismatch between promising preclinical observations and an unconfirmed human obesity claim—not a reason to recommend a supplier or protocol.